Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05592054
Other study ID # PROTECT-MT
Secondary ID
Status Suspended
Phase N/A
First received
Last updated
Start date November 20, 2022
Est. completion date December 31, 2024

Study information

Verified date January 2024
Source Changhai Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multi-center, prospective, randomized, open-label, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS.


Description:

The PROTECT-MT study is a prospective, multicenter, randomized controlled, open-label, blinded endpoint evaluation (PROBE) trial, and aims to determine the effectiveness of balloon guide catheter(BGC) as compared to standard guide catheter on functional outcome (modified Rankin Scale [mRS] score at Day 90 of 0-2) in patients with acute ischemic stroke due to anterior circulation large vessel occlusion. Primary Endpoints Functional outcome, defined as modified Rankin Scale (mRS) score of 0-2, at 90 days (±14 days) . Secondary Endpoints 1. Dichotomized mRS at 90 days after the operation (0-1 versus 2-6, 0-3 versus 4-6, 0-4 versus 5-6, 0-5 versus 6). 2. Change in stroke severity (NIHSS score) at 24 hours post treatment. 3. Change in stroke severity (NIHSS score) at 7 days post treatment or discharge (whichever occurs first). 4. Final infarct volume at 5-7 days 5. Technical success rate (defined as successfully navigating the guide catheter into the target vessel, and finishing the mechanical thrombectomy procedure without changing to another guide catheter). 6. Reperfusion outcome (eTICI 2b or greater, eTICI 2c or greater, eTICI 3) in final angiogram. 7. Reperfusion outcome (eTICI 2b or greater, eTICI 2c or greater, eTICI 3) after the first pass. 8. Time from groin puncture to successful reperfusion (eTICI 2b or greater, eTICI 2c or greater). 9. Percentage of subjects with acceptable revascularization quality (eTICI 2b or greater, eTICI 2c or greater) within 45 min of access. 10. Number of thrombectomy attempts (final). 11. Occurrence of emboli to a new territory. Safety Endpoints: 1. Deaths at 90 days (±14 days) post treatment. 2. Intracranial hemorrhage, symptomatic intracranial hemorrhage or asymptomatic intracranial hemorrhage at 7 days post treatment or discharge (whichever occurs first). 3. Other serious adverse events (SAEs) adjudicated by the Clinical Events Committee. 4. Any Procedural complications, including vessel dissection, arterial perforation, and femoral access complications, etc.


Recruitment information / eligibility

Status Suspended
Enrollment 1074
Est. completion date December 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age 18 years or older 2. Acute ischemic stroke, caused by a large vessel occlusion of the anterior circulation cerebral artery confirmed on brain imaging (intracranial carotid artery or middle M1/proximal M2) 3. Femoral artery puncture can be finished within 24 hours of symptom onset based on local practice 4. Pre-event modified Rankin Scale score 0-1 5. Written informed consent obtained (by patient or appropriate proxy, according to local requirements) Exclusion Criteria: 1. Intracranial hemorrhage on imaging 2. Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory 3. Excessive vascular access tortuosity that navigating BGCs would be impossible 4. Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neuro-thrombectomy device 5. Any other condition precludes performing MT procedure 6. Occlusions in multiple vascular territories confirmed on CTA/MRA 7. Pregnancy 8. Allergy to contrast agents 9. Patients refuse to cooperate or unable to tolerate interventional operation 10. Expected lifetime<90 days 11. Unlikely to participate in follow-up assessments 12. Any other condition that, in the opinion of the investigator, not suitable for BGCs

Study Design


Intervention

Procedure:
Balloon guide catheters (BGCs)
MT procedure with Balloon guide catheters (BGCs)
Standard guide catheter
MT procedure with standard guide catheter

Locations

Country Name City State
China Jianimin Liu Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Changhai Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Death Deaths at 90 days (±14 days) post treatment 90 days
Other Intracerebral hemorrhage (ICH) Intracranial hemorrhage, symptomatic intracranial hemorrhage or asymptomatic intracranial hemorrhage at 7 days post treatment or discharge (whichever occurs first) 7 days post treatment or discharge (whichever occurs first)
Other SAE Other serious adverse events (SAEs) adjudicated by the Clinical Events Committee 90 days
Other perioperative complications Any perioperative complications such as bleeding transformation, cerebral edema, vascular re occlusion, vascular dissection, new watershed embolism, contrast agent extravasation, puncture site hematoma, vascular spasm, vascular rupture, perforating branch tear, vascular perforation, stress ulcer, contrast agent hypersensitivity, contrast agent nephropathy, etc. Perioperative period
Primary Functional outcome defined as modified Rankin Scale (mRS) 90 days
Secondary Dichotomized mRS Dichotomized mRS (0-1 versus 2-6,0-2 versus 3-6,0-3 versus 4-6,0-4 versus 5-6,0-5 versus 6) 90 days
Secondary Change in stroke severity NIHSS 24 hours post treatment
Secondary Change in stroke severity NIHSS 7 days post treatment or discharge (whichever occurs first).
Secondary Technical success rate defined as successfully navigating the guide catheter into target vessel, and finishing the MT procedure without changing another guide catheter 24 hours after MT
Secondary Reperfusion outcome (eTICI 2b or greater ,eTICI 2c or greater, eTICI 3)in Final angiogram. 24 hours after MT
Secondary Reperfusion result (eTICI 2b or greater ,eTICI 2c or greater, eTICI 3) after First pass 24 hours after MT
Secondary Time from groin puncture to successful reperfusion ( eTICI 2c or greater) 24 hours after MT
Secondary Revascularization quality (eTICI 2c or greater) within 45 min of access 24 hours after MT
Secondary Thrombectomy attempt (final) Number of MT (final) 24 hours after MT
Secondary Occurrence of emboli to a new territory Occurrence of emboli to a new territory 90 days
Secondary Final infarct volume Final infarct volume at 5-7 days 5-7 days after MT
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Not yet recruiting NCT06437431 - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy Phase 2/Phase 3
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3